title: Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.
abstract: Persons of blood group O are at increased risk of developing cholera gravis. In a randomized, placebo-controlled, double-blind safety-immunogenicity trial of live oral cholera vaccine CVD 103-HgR in 5- to 9-year-old Chilean children, vibriocidal antibody seroconversion (74% overall) did not differ by blood group. However, the reciprocal geometric mean titer (GMT) in blood group O vaccines (GMT = 486) was higher than that in non-O vaccines (GMT = 179) (P < 0.02).
authors: Centro para Vacunas en Desarrollo-Chile.
authors: R
authors: R
authors: Lagos
authors: A
authors: A
authors: Avendaño
authors: V
authors: V
authors: Prado
authors: I
authors: I
authors: Horwitz
authors: S
authors: S
authors: Wasserman
authors: G
authors: G
authors: Losonsky
authors: S
authors: S
authors: Cryz
authors: J B
authors: JB
authors: Kaper
authors: M M
authors: MM
authors: Levine
mesh_terms: D000017:ABO Blood-Group System; D000907:Antibodies, Bacterial / Q000276:immunology*; D001770:Blood Bactericidal Activity; D002648:Child; D002677:Chile; D002771:Cholera / Q000276:immunology / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D006801:Humans; D014613:Vaccines, Attenuated / Q000276:immunology; D014734:Vibrio cholerae / Q000276:immunology*
chemical_list: D000017:ABO Blood-Group System; D000907:Antibodies, Bacterial; D022121:Cholera Vaccines; D014613:Vaccines, Attenuated